Cetera Advisor Networks LLC Genmab A/S Transaction History

Cetera Advisor Networks LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$26.43 - $32.77 $3,224 - $3,997	122 Added 1.39%	8,920 $266,000
Q4 2023 Feb 13, 2024	SELL	$27.94 - $35.44 $30,761 - $39,019	-1,101 Reduced 11.12%	8,798 $280,000
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $349,137 - $418,133	9,899 New	9,899 $349,000
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $394,479 - $549,237	11,671 New	11,671 $494,000
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $6,580 - $7,697	-199 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$20.05 - $33.89 $3,989 - $6,744	199 New	199 $7,000

234

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.